地昔帕明改善OSA患者上气道塌陷性并降低AHI
该安慰剂对照双盲随机交叉试验在14例OSA患者中评估地昔帕明对咽部塌陷性(Pcrit)和AHI的影响。地昔帕明降低主动Pcrit(-5.2 vs -1.9 cmH2O,p=0.049),但不降低被动Pcrit(p=0.135)。在肌肉补偿最小的患者中AHI下降更明显(r=0.71,p=0.009),且AHI下降由肌肉补偿改善驱动(r=0.72,p=0.009)。
要点
- 地昔帕明降低OSA患者主动咽部塌陷性(Pcrit),不改变被动Pcrit。
- 肌肉补偿最小的患者AHI下降更显著,AHI改善由肌肉补偿改善驱动。
- 去甲肾上腺素能刺激可能对肌肉补偿最小的OSA患者有效。
核心结论
- 在OSA患者中,地昔帕明通过去甲肾上腺素能刺激改善咽部塌陷性,可能对肌肉补偿最小的患者有效。
研究设计与样本
- 安慰剂对照、双盲、随机交叉试验,纳入14例OSA患者,睡前给予治疗或安慰剂。
- 通过持续气道正压(CPAP)操作评估被动和主动上气道肌肉条件下的咽部塌陷性(Pcrit)及 ventilation。
- 在脱离CPAP条件下量化AHI。
主要发现
- 地昔帕明降低主动Pcrit(中位数(四分位距)-5.2(4.3)cmH2O vs 安慰剂-1.9(2.7)cmH2O;p=0.049)。
- 地昔帕明未降低被动Pcrit(-2.2(3.4)vs -0.7(2.1)cmH2O;p=0.135)。
- 安慰剂条件下肌肉补偿(V'0,active-V'0,passive)越小的患者AHI下降越大(r=0.71,p=0.009)。
- AHI下降由肌肉补偿改善驱动(r=0.72,p=0.009)。
临床怎么用
- 地昔帕明可能作为肌肉补偿最小的OSA患者的潜在治疗选择。
局限性
- 样本量小(14例OSA患者),为生理学研究,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We recently demonstrated that desipramine reduces the sleep-related loss of upper airway dilator muscle activity and reduces pharyngeal collapsibility in healthy humans without obstructive sleep apnoea (OSA). The aim of the present physiological study was to determine the effects of desipramine on upper airway collapsibility and apnoea-hypopnea index (AHI) in OSA patients.A placebo-controlled, double-blind, randomised crossover trial in 14 OSA patients was performed. Participants received treatment or placebo in randomised order before sleep. Pharyngeal collapsibility (critical collapsing pressure of the upper airway (Pcrit)) and ventilation under both passive (V'0,passive) and active (V'0,active) upper airway muscle conditions were evaluated with continuous positive airway pressure (CPAP) manipulation. AHI was quantified off CPAP.Desipramine reduced active Pcrit (median (interquartile range) -5.2 (4.3) cmH2O on desipramine versus -1.9 (2.7) cmH2O on placebo; p=0.049) but not passive Pcrit (-2.2 (3.4) versus -0.7 (2.1) cmH2O; p=0.135). A greater reduction in AHI occurred in those with minimal muscle compensation (defined as V'0,active-V'0,passive) on placebo (r=0.71, p=0.009). The reduction in AHI was driven by the improvement in muscle compensation (r=0.72, p=0.009).In OSA patients, noradrenergic stimulation with desipramine improves pharyngeal collapsibility and may be an effective treatment in patients with minimal upper airway muscle compensation.
引用
- Taranto-Montemurro L, Sands SA, Edwards BA, et al. Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J. 2016. PMID: 27799387. doi:10.1183/13993003.00823-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。